Browse

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.